Efficacy of natural killer T and gammadelta T cells in mesothelin-targeted immunotherapy of pancreatic cancer

Efficacy of natural killer T and gammadelta T cells in mesothelin-targeted immunotherapy of pancreatic cancer

Current pancreatic cancer immunotherapy focused on alphabeta (αβ) T cells, either through CD3-engaged bispecific antibodies or CAR-T. Despite their promise, dose-limited toxicity (DLT) remains a challenge in clinical practice. In light of these concerns, there is a growing interest in exploring alte...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yuankui Zhu, Yaxi Yang, Linghe Yue, Lei Wan, Xuqian Ma, Qing Yang, Xuan Tian, Yuguan Li, Ke Wang, Shaozhong Wei, Dianbao Zuo, Mingqian Feng
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-02-01
Series:	Frontiers in Immunology
Subjects:	NKT γδT PBMCs bispecific antibody pancreatic tumor
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1524899/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Urolithin A increases the natural killer activity of PBMCs in patients with prostate cancer
by: Vladimir Rogovskii, et al.
Published: (2025-01-01)

Expression of toll-like receptors (tlrs) in the equine peripheral blood mononuclear cells (pbmcs) during the early pregnancy and estrous cycle
by: Ercan Kurar, et al.

γδ T Cell‐mediated Tumor Immunity is Tightly Regulated by STING and TGF‐β Signaling Pathways
by: Jing Luo, et al.
Published: (2025-01-01)

Low-exhaustion peripheral circulating γδ T cells serve as a biomarker for predicting the clinical benefit rate of non-small cell lung cancer (NSCLC) patients to chemotherapy or targeted therapy: a single-center retrospective study
by: Dongdong Zhang, et al.
Published: (2025-01-01)

Natural killer cell engagers for cancer immunotherapy
by: Shahryar Khoshtinat Nikkhoi, et al.
Published: (2025-01-01)

Exosomal PVRL4 Promotes Lung Adenocarcinoma Progression by Enhancing the Generation of Myeloid‐Derived Suppressor Cell‐Secreted TGF‐β1
by: Yahai Liang, et al.
Published: (2025-01-01)

Structural insights into antibody-based immunotherapy for hepatocellular carcinoma
by: Masaud Shah, et al.
Published: (2025-01-01)

A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer
by: Peter Jung, et al.
Published: (2024-12-01)

Rapid and non-destructive classification of rice seeds with different flavors: an approach based on HPFasterNet
by: Helong Yu, et al.
Published: (2025-01-01)

Lipid Antigens: Revealing the Hidden Players in Adaptive Immune Responses
by: Tamana Eskandari, et al.
Published: (2025-01-01)

Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers
by: Bill Liao, et al.
Published: (2024-12-01)

Editorial: Cognate recognition, functional properties and immunotherapeutic applications of iNKT cells: leveling the road to the clinic
by: A. Raul Castaño, et al.
Published: (2025-01-01)

Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers
by: Ammelie Svea Boje, et al.
Published: (2024-12-01)

Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment
by: Rahul Navab, et al.
Published: (2025-01-01)

PBMCs gene expression predicts liver fibrosis regression after successful HCV therapy in HIV/HCV-coinfected patients
by: Ana Virseda-Berdices, et al.
Published: (2025-01-01)

Spatial analysis of digital economy and its driving factors: A case study of the Yangtze River Delta City Cluster in China.
by: Haidong Zhong, et al.
Published: (2024-01-01)

Model-assisted analysis on the response of tomato fruit growth to source-sink ratio regulated by water and nitrogen
by: Huiping Zhou, et al.
Published: (2025-02-01)

Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy
by: Amelia C. McCue, et al.
Published: (2024-12-01)

BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA
by: Ugo Testa, et al.
Published: (2024-08-01)

Tarlatamab and the Future of Immunotherapy: A New Approach to Small Cell Lung Cancer
by: Raza Ur Rehman, MBBS, et al.
Published: (2025-01-01)

A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy
by: Gerhard Frey, et al.
Published: (2024-12-01)

Expansion of Gammadelta T Cells from Cord Blood: A Therapeutical Possibility
by: Sofia Berglund, et al.
Published: (2018-01-01)

Developability considerations for bispecific and multispecific antibodies
by: Alaa Amash, et al.
Published: (2024-12-01)

A comparative study of the developability of full-length antibodies, fragments, and bispecific formats reveals higher stability risks for engineered constructs
by: Itzel Condado-Morales, et al.
Published: (2024-12-01)

Trade-Offs Between Hydraulic Efficiency and Safety in Cotton (<i>Gossypium hirsutum</i> L.) Stems Under Elevated CO<sub>2</sub> and Salt Stress
by: Qing Zhao, et al.
Published: (2025-01-01)

Design of a humanized CD40 agonist antibody with specific properties using AlphaFold2 and development of an anti-PD-L1/CD40 bispecific antibody for cancer immunotherapy
by: Kun Du, et al.
Published: (2025-02-01)

Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation
by: Oana Hangiu, et al.
Published: (2025-01-01)

Improving CD3 bispecific antibody therapy in solid tumors using combination strategies
by: Katy Lloyd, et al.
Published: (2025-02-01)

IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine release
by: John S. Schardt, et al.
Published: (2024-12-01)

Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions
by: Michael Mullin, et al.
Published: (2024-12-01)

Prodrug-based bispecific antibodies for cancer therapy: advances and future directions
by: Zhijuan Ai, et al.
Published: (2025-01-01)

Risk of infections in bispecific antibody therapy for multiple myeloma: a comprehensive review of literature
by: Fahad Alshammari, et al.
Published: (2025-12-01)

Interaction between biochar particle size and soil salinity levels on soil properties and tomato yield
by: Zhuqing Wu, et al.
Published: (2025-02-01)

Transcriptome-Wide Identification of miRNAs and Their Targets During Riboflavin-Promoted Dormancy Release in <i>Lilium</i> ‘Siberia’
by: Xiaoping Xu, et al.
Published: (2024-12-01)

A novel label-free method to determine equilibrium dissociation constants of antibodies binding to cell surface proteins
by: Eilyn R. Lacy, et al.
Published: (2025-01-01)

Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review
by: Joseph Sassine, et al.
Published: (2025-01-01)

Toll-Like Receptors in Natural Killer Cells and Their Application for Immunotherapy
by: Ji-Yoon Noh, et al.
Published: (2020-01-01)

A humanized anti-MSLN×4-1BB bispecific antibody exhibits potent antitumour activity through 4-1BB signaling activation and fc function without systemic toxicity
by: Da-yan Zhang, et al.
Published: (2025-01-01)

Pain in pancreatitis: issue and ways out
by: A. V. Okhlobystin
Published: (2012-02-01)

Primary Pancreatic Hepatoid Carcinoma: A Case Report and Literature Review
by: Tyng-Wei Yang, et al.
Published: (2023-07-01)